BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $26,668.74 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the transaction, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 26th, Troy Wichterman sold 581 shares of BioLife Solutions stock. The shares were sold at an average price of $27.20, for a total value of $15,803.20.
• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The shares were sold at an average price of $26.19, for a total value of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The stock was sold at an average price of $23.15, for a total value of $20,696.10.

BioLife Solutions Trading Down 3.9 %

Shares of BLFS stock opened at $26.61 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $28.88. The stock’s fifty day moving average price is $25.99 and its two-hundred day moving average price is $24.29. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a market cap of $1.23 billion, a PE ratio of -25.10 and a beta of 1.92.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BLFS. Mutual of America Capital Management LLC acquired a new stake in shares of BioLife Solutions in the 2nd quarter valued at approximately $8,592,000. Rockefeller Capital Management L.P. boosted its position in BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after buying an additional 262,504 shares in the last quarter. State Street Corp grew its stake in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of BioLife Solutions by 261.5% during the second quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock worth $2,726,000 after buying an additional 92,021 shares in the last quarter. Finally, Fred Alger Management LLC lifted its stake in shares of BioLife Solutions by 6.0% in the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after acquiring an additional 88,840 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

BLFS has been the topic of several research reports. HC Wainwright decreased their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Benchmark reiterated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. TD Cowen increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. KeyCorp lifted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Finally, Northland Securities increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.43.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.